UCL Discovery
UCL home » Library Services » Electronic resources » UCL Discovery

Landscape of activating cancer mutations in FGFR kinases and their differential responses to inhibitors in clinical use

Patani, H; Bunney, TD; Thiyagarajan, N; Norman, RA; Ogg, D; Breed, J; Ashford, P; ... Katan, M; + view all (2016) Landscape of activating cancer mutations in FGFR kinases and their differential responses to inhibitors in clinical use. Oncotarget , 7 (17) pp. 24252-24268. 10.18632/oncotarget.8132. Green open access

[thumbnail of Patani et al. Oncotarget 2016.pdf]
Preview
Text
Patani et al. Oncotarget 2016.pdf - Accepted Version

Download (6MB) | Preview
[thumbnail of Supplemental.pdf]
Preview
Text
Supplemental.pdf - Accepted Version

Download (4MB) | Preview

Abstract

Frequent genetic alterations discovered in FGFRs and evidence implicating some as drivers in diverse tumors has been accompanied by rapid progress in targeting FGFRs for anticancer treatments. Wider assessment of the impact of genetic changes on the activation state and drug responses is needed to better link the genomic data and treatment options. We here apply a direct comparative and comprehensive analysis of FGFR3 kinase domain variants representing the diversity of point-mutations reported in this domain. We reinforce the importance of N540K and K650E and establish that not all highly activating mutations (for example R669G) occur at high-frequency and conversely, that some "hotspots" may not be linked to activation. Further structural characterization consolidates a mechanistic view of FGFR kinase activation and extends insights into drug binding. Importantly, using several inhibitors of particular clinical interest (AZD4547, BGJ-398, TKI258, JNJ42756493 and AP24534), we find that some activating mutations (including different replacements of the same residue) result in distinct changes in their efficacy. Considering that there is no approved inhibitor for anticancer treatments based on FGFR-targeting, this information will be immediately translatable to ongoing clinical trials.

Type: Article
Title: Landscape of activating cancer mutations in FGFR kinases and their differential responses to inhibitors in clinical use
Open access status: An open access version is available from UCL Discovery
DOI: 10.18632/oncotarget.8132
Publisher version: http://dx.doi.org/10.18632/oncotarget.8132
Language: English
Additional information: Copyright @ 2008-2016 Impact Journals, LLC. All rights reserved. Impact Journals is a trademark of Impact Journals, LLC. All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License. PII: 8132 http://creativecommons.org/licenses/by/3.0/
Keywords: Cancer mutations, precision medicine, receptor tyrosine kinases, resistance, small molecule inhibitors
UCL classification: UCL
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Life Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Life Sciences > Div of Biosciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Life Sciences > Div of Biosciences > Structural and Molecular Biology
URI: https://discovery.ucl.ac.uk/id/eprint/1477202
Downloads since deposit
434Downloads
Download activity - last month
Download activity - last 12 months
Downloads by country - last 12 months

Archive Staff Only

View Item View Item